Core Insights - QuidelOrtho Corporation reported a total revenue of $614 million for Q2 2025, a decrease of 3.6% compared to $637 million in the prior year period, primarily due to lower COVID-19 and Donor Screening revenue [3][14] - The company achieved adjusted diluted EPS of $0.12, compared to an adjusted diluted loss per share of ($0.07) in the prior year period, indicating a significant improvement in profitability metrics [5][14] - The company reiterated its full-year 2025 financial guidance, projecting total revenues between $2.60 billion and $2.81 billion and adjusted EBITDA between $575 million and $615 million [7][14] Financial Performance - Total revenue for Q2 2025 was $614 million, down from $637 million in Q2 2024, with a notable decrease in COVID-19 related revenue [3][14] - GAAP diluted loss per share was $3.77, compared to a loss of $2.20 in the prior year, reflecting increased operational challenges [4][14] - Adjusted EBITDA for Q2 2025 was $107 million, up from $90 million in the prior year, with an adjusted EBITDA margin of 17%, a 330 basis point improvement [5][14] Operational Highlights - The company achieved $100 million in annualized cost savings through various initiatives, which contributed to improved margins [2][14] - Labs revenue grew by 4% as reported and 5% in constant currency, indicating strong performance in this segment [14] - The company announced its intention to acquire LEX Diagnostics and initiated a major manufacturing site consolidation [2][14] Revenue Breakdown - Non-respiratory revenue was $567 million, a decrease of 2% year-over-year, while excluding Donor Screening, it grew by 1% in constant currency [14][25] - Respiratory revenue was $47 million, a 20% decrease primarily driven by lower COVID-19 revenue [14] - Immunohematology revenue grew by 4% as reported and 3% in constant currency, showcasing resilience in this area [14] Guidance and Future Outlook - The company maintains its fiscal 2025 guidance, expecting total revenues of $2.60 billion to $2.81 billion and adjusted diluted EPS between $2.07 and $2.57 [7][14] - The anticipated impact of foreign currency exchange is expected to be neutral for the full year based on rates as of July 27, 2025 [7][14] - The company is focused on delivering sustainable value over time for shareholders, customers, and employees [2][14]

Core Insights - QuidelOrtho received three awards and top rankings in the 2025 IMV ServiceTrak Awards, highlighting excellence in customer satisfaction within the diagnostics industry [1][8] - The company achieved a 17-point increase in Net Promoter Score (NPS), indicating significant improvements in customer loyalty and satisfaction [2][8] - QuidelOrtho's success is attributed to investments in customer experience initiatives and employee development, enhancing product quality and service [3][4] Awards and Rankings - QuidelOrtho was recognized for the best overall system performance in both Chemistry and Integrated Systems categories [8] - The company achieved the highest rankings in several key areas, including: - 1 Overall Net Promoter Score (NPS) by Manufacturer - 1 Overall Manufacturer Performance - 1 Overall Service Engineer Performance - 1 Overall Training Performance [8][9] Customer-Centric Approach - The company prioritizes customer beliefs and values, focusing on delivering solutions that enhance laboratory efficiency and outcomes [3][4] - QuidelOrtho's commitment to ongoing innovation and customer-focused solutions is evident in their QuidelOrthoCQ™ offerings, which aim to support customer success [5][6]

Core Insights - The podcast episode discusses the increasing complexities of substance use detection and care in emergency departments, emphasizing the need for rapid diagnostic testing to prevent drug overdose deaths [3][8] - Vonda McAllister, Director of Global Product Management at QuidelOrtho, highlights the importance of continuous monitoring and comprehensive toxicology screening in addressing the crisis of drug overdoses [5] Industry Trends - There is a rising prevalence of potent synthetic drugs such as fentanyl, xylazine, and nitazines, which complicates overdose presentations [8] - The limitations of Narcan (naloxone) are becoming evident, with a growing need for repeated doses due to the potency of new opioid analogs [8] - California's "Tyler's Law" mandates fentanyl testing in suspected overdose cases, reflecting a legislative response to the crisis [8] Company Overview - QuidelOrtho Corporation is a global provider of innovative diagnostic testing solutions, focusing on various health areas including infectious diseases and cardiac biomarkers [7] - The company aims to transform diagnostics into a healthier future through science, innovation, and accessibility [7]

Core Viewpoint - QuidelOrtho Corporation will report its financial results for the second quarter of 2025 on August 5, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 2:00 p.m. PT / 5:00 p.m. ET on the same day [2] - Interested parties can access the call via the Company's Investor Relations page or by phone using specific dial-in numbers [2] Replay Availability - A replay of the conference call will be available shortly after the event on the Company's Investor Relations page [3] Company Overview - QuidelOrtho Corporation is a leader in in vitro diagnostics, focusing on innovative solutions that enhance understanding and action in healthcare [4] - The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing reliable diagnostics across various settings [4][5]

Group 1 - QuidelOrtho Corporation is a leader in in vitro diagnostics, focusing on transforming data into actionable insights for healthcare [4][5]. - The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing reliable diagnostics across various settings [4]. - QuidelOrtho emphasizes innovation and collaboration with global healthcare customers to enhance diagnostic solutions [5]. Group 2 - A session titled "Real Labs, Real Decisions with Actionable Six Sigma Metrics" is scheduled for July 29, 2025, at the McCormick Convention Center in Chicago [1]. - The session will feature a panel of experts, including Dr. Jared Jaeger from QuidelOrtho and other professionals from notable institutions [2]. - Attendees can register for the session or access a recording if unable to attend [3].

Core Insights - The collaboration between QuidelOrtho and BÜHLMANN Laboratories AG focuses on addressing key healthcare trends such as non-invasive diagnostic tools, cost-effective healthcare solutions, and the emphasis on gastrointestinal and pancreatic health [1][4] - The fCAL and fPELA turbo assays represent significant advancements in the diagnosis of inflammatory bowel disease (IBD) and pancreatic insufficiency, providing fast results that enhance patient care [2][4] - The integration of CALEX Cap technology simplifies sample extraction and preparation, improving operational efficiency and clinical accuracy [3][4] Company Overview - QuidelOrtho Corporation is a leader in in vitro diagnostics, offering solutions that transform data into actionable insights across various healthcare settings [6][7] - BÜHLMANN Laboratories AG has been developing innovative in-vitro diagnostic assays for nearly 50 years, focusing on chemistry and immunological testing [9] Product Features - The fCAL and fPELA turbo assays provide rapid results in less than 10 minutes, with a 90-day on-analyzer stability and compatibility with VITROS Automation Solutions [8] - The collaboration enhances flexibility in sample handling and processing, catering to a wide variety of sample collection methods [4]

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. As we continue driving productivity and efficiency within our R&D team, these additions underscore QuidelOrtho's commitment to building a high-performance organization rooted in scientific excellence, customer trust and global scale. QuidelOrtho is dedicated to advancing d ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these ...

Core Viewpoint - QuidelOrtho (QDEL) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to significant stock price movements when estimates are revised [4]. Company Performance and Outlook - The upgrade indicates an improvement in QuidelOrtho's underlying business, suggesting that investors may respond positively by driving the stock price higher [5][10]. - For the fiscal year ending December 2025, QuidelOrtho is expected to earn $2.39 per share, with a 4.6% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - QuidelOrtho's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

Core Viewpoint - The article emphasizes the importance of value investing and highlights QuidelOrtho (QDEL) as a strong value stock based on various financial metrics [2][4][7] Group 1: Company Overview - QuidelOrtho (QDEL) currently holds a Zacks Rank of 2 (Buy) and a Value grade of A, indicating strong potential for value investors [4] - The stock has a P/E ratio of 10.54, significantly lower than the industry average P/E of 21.08, suggesting it may be undervalued [4] - Over the past 52 weeks, QDEL's Forward P/E has fluctuated between a high of 25.36 and a low of 9.36, with a median of 14.18 [4] Group 2: Financial Metrics - QDEL has a P/S ratio of 0.69, compared to the industry's average P/S of 1.34, further indicating potential undervaluation [5] - The company’s P/CF ratio stands at 11.91, which is attractive relative to the industry average P/CF of 12 [6] - QDEL's P/CF has ranged from a high of 15.25 to a low of 5.04 over the past year, with a median of 8.88, showcasing its strong cash flow outlook [6] Group 3: Investment Outlook - The combination of the aforementioned metrics suggests that QuidelOrtho is likely undervalued, making it one of the strongest value stocks in the market [7]